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INTRODUCTION

Completion of a map of the human genome in 2003,1 the
coupling
of
biology
and
information
technology
("bioinformatics"), 2 and the pace of advancement of this and
related fields have given rise to expectations that a "genomics
revolution" will transform the practice of medicine. 3 Some of the
greatest expectations are placed in the fields of population health,
including database compilation;4 the use of pharmacogenomics and
5
pharmacogenetics to genetically profile responses to drugs;
haplotype mapping, meaning identification of linkages between
genetic variants and populations; 6 and individualized medicine
based upon genetic profiling.
1. HGP was driven to completion years ahead of schedule through
competition between industry and government-led teams that ultimately joined
forces to declare a joint victory. See generally 291 Science 1145 (Feb. 16,
2001) (issue entitled "The Human Genome"); 409 Nature 745 (Feb. 15, 2001)
(issue dedicated to the release of a draft map of the human genome).
Information about the Human Genome Project may be obtained from the
National Human Genome Research Institute (NHGRI), available at
www.nhgri.nih.gov.
2. See generally Essentials of Genomics and Bioinformatics (C.W. Sensen
ed., 2005).
3. See generally James D. Watson, DNA: The Secret of Life (Alfred A.
Knopf ed., 2003); The Genomic Revolution: Unveiling the Unity of Life
(Michael Yudell & Robert DeSalle eds., 2002) (concluding, "The knowledge
gained [from HGP] could cure cancer, prevent heart disease, and feed millions.
At the same time, its improper use can discriminate, stigmatize, and cheapen life
through frivolous enhancement technologies."); Allen Guttmacher & Francis
Collins, Welcome to the Genomic Era, 349 New Eng. J. Med. 996-98 (2004),
available at www.nejm.org; Climbing the Helical Staircase: A Survey of
Biotechnology, The Economist, Mar. 29, 2003, at 1-24.
4. See generally Symposium, Regulation of Biobanks, 33 J.L.Med. &
Ethics 1-188 (Mark Rothstein & Bartha Knoppers eds., 2005).
5. Lars Noah, The Coming Pharmacogenomics Revolution: Tailoring
Drugsto FitPatients' GeneticProfiles,43 Jurimetrics J. 1 (2002).
6. See generally HapMap Homepage, International HapMap Project,
www.hapmap.org;
National Genome Research
Institute Homepage,
www.genome.gov.
7. See generally Watson, supranote 3; Guttmacher & Collins, supra note
3; Noah, supranote 5.
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To contribute to prospective discussion of the impact of
genomics on health care and society, the Pennington Biomedical
Research Center, LSU; the Paul M. Hebert Law Center, LSU; and
the University of Montreal's Centre for Public Law Research
collaborated to host a live symposium on February 4-6, 2004, with
the mission of assessing the scientific expectations and social
implications being placed on the genomics revolution.8 This
symposium, The Genomics Revolution? Science, Law andPolicy,
was organized into three sessions centered on case study
applications of genomics.
Each case study opened with
presentations to explain and address science expectations, and
those presentations were followed by panel presentations and
discussions of associated law and policy issues.
The first session focused on the topic of population health. The
objective was to probe the extent to which genomics will introduce
meaningful risk predictions for common diseases in the context of
health populations. Discussion focused on three common diseases:
heart disease, diabetes, and obesity.
The second session addressed pharmacogenomics.
This
discussion centered on whether pharmacogenomics will deliver
tangible health care returns, when, for whom, and at what costs.
The third session was on haplotype mapping. The central
question was, "Where will haplotype mapping take us?"
The live symposium succeeded in generating engaging
presentations and interactive discussion drawn from the varied
disciplines of science, medicine, and law-policy.
We, the
conference Co-Chairs and the LouisianaLaw Review, are delighted
to publish this special proceedings symposium with contributions
drawn from presentation transcripts. The symposium begins with
overview presentations by Dr. Michael McGinnis and Professor
Bartha Knoppers. In Population Health and the Influence of
Medical and Scientific Advances, Dr. McGinnis explains that the
application of genomic technologies to medical care has the
potential to lessen our dependence on "halfway technologies"treatments that turn diseases into chronic conditions rather than
8. These published proceedings do not necessarily reflect changes made
thereafter, though most of the contributors have periodically updated their pieces
during the production process.
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eliminating them-and thereby both improve human health and
reduce costs. 9
Professor Knoppers explains how four phenomenaovergeneralization,
exceptionalism,
and
reductionism,
commercialization-are
affecting how population health,
pharmacogenomics, and the haplotype map will be received.' 0 She
concludes in Overview of Law and Policy Challenges that, "if we
stop equating tissues with humans and genes with persons,... we
might have some possibility in the next decade of having a more
international ' approach, more harmonization and, thus, true
collaboration. I
The case study on population health is addressed through
presentations by Dr. Paula Yoon, Professor Michael Malinowski,
Robert Wells, and Professor Hank Greely. In Risk Predictionfor
Common Diseases, Dr. Yoon explains that scale matters in the
conversion of new science tools and processes into disease
treatment and prevention. 12 In her words, "We need large-scale,
population-based collaborative research because, when you start
looking at multiple genes and multiple environmental factors to
stratify risks,13 you need big numbers to find meaningful
associations."'
Professor Malinowski builds upon the premise that biobanking,
the organized collection of DNA and accompanying medical
information from human populations,' 4 is necessary to meet the
pressing needs of the genomics research community. In Taking
Genomics to the BioBank: Access to Human Biological Samples
and Medical Information, he encourages drawing from
biotechnology technology transfer and development experience to

9. J. Michael McGinnis, PopulationHealth and the Influence of Medical
andScientific Advances, 66 La. L. Rev. (Special Issue) 9, 19-20, (2005).
10. Bartha Maria Knoppers, Overview of Law and Policy Challenges, 66
La. L. Rev. (Special Issue) 21 (2005).
11. Id. at30-31.
12. Paula W. Yoon, Risk Predictionfor Common Diseases, 66 La. L. Rev.
(Special Issue) 33 (2005).
13. Id. at 40.
14. For
an excellent, timely treatment of biobanking, see
Symposium:Biobanks, supranote 4, at 1-188.
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frame and address questions, and to move science, medicine, and
biobanking forward in a responsible manner.15
In Intellectual Property/Ownership Issues, Robert Wells
addresses the challenge of finding a balance in intellectual property
policy between the often conflicting goals of providing commercial
incentives and maximizing the research community's access to the
means to expeditiously advance the medical application of
genomics. 1 He proposes a thoughtful technology transfer and
development approach that "would bring some of the interested
players to the table and try to create the kind of framework that at
least allows basic research to go forward and researchers to feel
like they are not going to get a cease and desist order
from a
7
patent-holder somewhere trying to block their work.'
Professor Greely addresses the social, ethical, and legal issues
generally applicable to biobanking, and then the special problems
that arise from biobanking in particular populations. In Population
Participationand Other Factorsthat Impact the Compilationand
the Utility ofResultingDatabases,he emphasizes that "We are the
people, we are the generation that has both the opportunity and the
duty to create some settled expectations, some rules, some
guidelines, some standards, about how people
in biobanks and
' 8
populations in biobanks should be treated."'
Pharmacogenomics,' 9 the topic of the second case study, is
addressed through presentations by Dr. Janet Woodcock, Dr.
Jeffrey Moe, and Professor Mark Rothstein. Dr. Woodcock
addresses existing and developing public policy around the science
of pharmacogenomics and how the field will be integrated into
new drug development, and she does so with the intention of
broadening discussion beyond the scientific community and the
Food and Drug Administration.
In FDA Policy on
15. Michael J. Malinowski, Taking Genomics to the Biobank: Access to
Human Biological Samples and Medical Information, 66 La. L. Rev. (Special
Issue) 43 (2005).
16. Robert Wells, Intellectual Property/OwnershipIssues, 66 La. L. Rev.
(Special Issue) 69 (2005).
17. Id. at 77.
18. Henry T. Greely, Population Participationand Other Factors that
Impact the Compilation and the Utility of Resulting Databases,66 La. L. Rev.
(Special Issue) 79, 90 (2005).
19. See supranote 5 and accompanying text.
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PharmacogenomicData in DrugDevelopment, she concludes that
"Pharmacogenomics will introduce deeper understanding [in drug
20
development], but most likely with high clinical complexity."
Dr. Moe and Professor Rothstein both look beyond drug
development to the market and law-policy implications of folding
medicinal products created through pharmacogenomics into health
care systems.
In Commercialization Considerations for
Individualized Diagnostic and Drug Therapies Resulting from
Pharmacogenomics, Dr. Moe identifies specific challenges to
commercializing pharmacogenomics. He concludes that, "With all
these commercialization challenges in mind, my own judgment is
that pharmacogenomics will most likely exacerbate the current
challenges we face in health care rather than solve them." 2' His
reasoning is that "We are struggling, and many times failing, to
practice the current standard of care based on population-level
understanding, much less attempting2 to take the standard of care to
a higher level of individualization."
Professor Rothstein addresses liability issues from the
perspectives of drug manufacturers and health care providers. He
concludes that it "remains to be seen whether personal injury
lawsuits based on alleged failure to properly prescribe, dose,
dispense, and administer medications will increase as a result of
the growing availability of pharmacogenomic-based drugs," 23 and

that "these could well be a significant increase in the potential
liability of pharmacists and nurses as well as physicians. ' 24 He
closes by emphasizing the importance of not "allow[ing] liability
concerns to paralyze either drug development or the clinical
introduction of safer and more effective pharmacogenomic
25
medications."

20.

Janet Woodcock, FDA Policy on Pharmacogenomic Data in Drug

Development, 66 La. L. Rev. (Special Issue) 91, 102 (2005).
21. Jeffrey L. Moe, Commercialization Considerationsfor Individualized
Diagnosticand Drug Therapies Resultingfrom Pharmacogenomics,66 La. L.

Rev. (Special Issue) 103, 115 (2005).
22. Id.
23. Mark A. Rothstein, Liability Issues in Pharmacogenomics,66 La. L.
Rev. (Special Issue) 117, 123 (2005).

24. Id.
25. Id. at 124.
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Haplotype mapping is the subject of the third case study. In
their presentations, Professors Clayton and Ossorio explain the
ethical, legal, social, and political implications already identified in
the context of the HapMap project and illustrate that, regardless of
the validity of the underlying scientific premises, the effort has
already generated valuable returns. In Implicationsfor Existing
Law/Regulations, Professor Clayton draws from her experience as
Co-Chair, with Professor Knoppers, of the HapMap Ethics
Committee, and emphasizes that "HapMap is a step. It is a
hypothesis. ' '26 She shares her hope that, in the process of taking
that step and testing the hypothesis, "we have managed to learn
some things about how better to proceed in a way that creates trust
with people who are going to be involved
in genetic epidemiology
27
research as research participants.
In Race, Genetic Variation, and the Haplotype Mapping
Project, Professor Ossorio explains the selection of HapMap
participants in some detail, and she raises probing questions about
the potential impact of the project and similar genetic studies on
contemporary and future notions of race. 28 Her discussion forces
thoughtful reflection on how race has been defined thus far, and
potential harms and benefits of looking at racial and ethnic
differences in the context of contemporary genetic science.
As a collective whole, we hope that this multidisciplinary
symposium makes a significant contribution to the law literature
and, more importantly, to the law and policy that will shape the
future of science, medicine, and society. Our sincere appreciation
to each of the conference faculty for the collegiality, talent, and
many individual efforts that made this symposium possible.

26. Ellen Wright Clayton, Implicationsfor Existing Law/Regulations, 66
La. L. Rev. (Special Issue) 125, 129 (2005).
27. Id. at 129.
28. Pilar N. Ossorio, Race, Genetic Variation and the Haplotype Mapping
Project,66 La. L. Rev. (Special Issue) 131 (2005).

